General
Preferred name
TOLBUTAMIDE
Synonyms
HLS 831 ()
TOLBUTAMIDE SODIUM, STERILE ()
Tolbutamide?(HLS 831) ()
NSC-23813 ()
Orinase ()
Diabetamid ()
Glyconon ()
Tolbutamidum ()
Butamide ()
Arkozal ()
NSC-87833 ()
Pramidex ()
1-butyl-3-(p-tolylsulfonyl)urea ()
Rastinon ()
Ipoglicone ()
Willbutamide ()
Tolbutamide Sodium ()
Orinase Diagnostic ()
Sodium tolbutamide ()
Tolbutamide sodium salt ()
Tolbutamide ()
Tolbutamide-d9 ()
P&D ID
PD001726
CAS
64-77-7
473-41-6
100735-34-0
1219794-57-6
Tags
natural product
drug
available
Approved by
FDA
First approval
1961
Drug Status
investigational
approved
Drug indication
Antidiabetic,Diagnostic Aid (diabetes)
Diagnostic Aid (diabetes)
Non-insulin dependent diabetes
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Readily absorbed following oral administration. Tolbutamide is detectable in plasma 30-60 minutes following oral administration of a single dose with peak plasma concentrations occurring within 3-5 hours. ; ; Absorption is unaltered if taken with food but is increased with high pH.
DESCRIPTION A sulfonylurea family drug inhibiting sulfonylurea receptor 1 (ABCC8)/Kir6.2 ( KCNJ11). (GtoPdb)
DESCRIPTION Oral hypoglycemic agent; stimulates pancreatic islet cells to secrete insulin (LOPAC library)
DESCRIPTION Tolbutamide is an inhibitor of potassium channel, used for type II diabetes. (BOC Sciences Bioactive Compounds)
Compound Sets
28
BOC Sciences Bioactive Compounds
tolbutamide-cas-64-77-7-item-84-304715
Cayman Chemical Bioactives
19888
30738
ChEMBL Approved Drugs
CHEMBL782
CHEMBL1200874
ChEMBL Drugs
CHEMBL782
CHEMBL1200874
Concise Guide to Pharmacology 2017/18
6848
Concise Guide to Pharmacology 2019/20
6848
Concise Guide to Pharmacology 2021/22
6848
Concise Guide to Pharmacology 2023/24
6848
Drug Repurposing Hub
DrugBank
DB01124
DrugBank Approved Drugs
DB01124
DrugCentral
2696
DrugCentral Approved Drugs
2696
DrugMAP
DM02AWV
DrugMAP Approved Drugs
DM02AWV
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
6848
LOPAC library
MedChem Express Bioactive Compound Library
HY-B0401
NCATS Inxight Approved Drugs
982XCM1FOI
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
tolbutamide
TargetMol Bioactive Compound Library
T1054
The Spectrum Collection
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
270.1
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
1.78
TPSA
75.27
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Insulin
Pathway
Membrane Transporter/Ion Channel
Target
Potassium Channel
ABCC8, KCNJ1, KCNJ11, KCNJ8
Na+/K+ ATPase
Indication
diabetes mellitus
MOA
ATP channel blocker
Therapeutic Class
Hypoglycemic Agents
Source data